Clinical trial
A Stratified Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase I/IIa Clinical Trial to Assess the Safety and Efficacy of a Single Intravenous Dose of Isolated, Placental, Mesenchymal Stem Cell-derived Extracellular Vesicles for the Treatment of COVID-19 Symptoms in Adults With Mild to Moderate Illness
NCT07664696 is registered in ClinicalTrials.gov with Kimera Labs Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Stratified Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase I/IIa Clinical Trial to Assess the Safety and Efficacy of a Single Intravenous Dose of Isolated, Placental, Mesenchymal Stem Cell-derived Extracellular Vesicles for the Treatment of COVID-19 Symptoms in Adults With Mild to Moderate Illness
- Lead sponsor
- Kimera Labs Inc.
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- December 31, 2028
- Enrollment
- 64 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.